Abstract
Mastocytosis is one of the eight subcategories of the myeloproliferative neoplasms of the classification of lymphoid and hematopoietic tissues’ tumors of 2008 of World Health Organization; it is an heterogeneous group of myeloproliferative diseases characterized by the excessive proliferation of atypical mastocytes in morphological and immunophenotype terms, besides the cumulus of these cells in one or several organs or tissues, including skin, bone marrow, liver, spleen and lymph nodes.References
Brockow K, Jofer C, Behrendt Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-232.
Takemoto C. Mast cells-friend or foe? J Pediatr Hematol Oncol 2010;32:342-344.
Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005;114:61-69.
Conde-Fernandes I, Anjos-Texeira M, Freitas I, et al. Adult mastocytosis: a review of the Santo Antonio Hospital’s experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease. An Bras Dermatol 2014;89:55-66.
Sanchez-Muñoz L, Teodosio C, Morgado JM, et al. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011;103:333-359.
Amorim Oliveira AC, Mihon CE, Silva M, Galzerano A. Systemic mastocytosis-a diagnostic challenge. Revista Brasileira de Hematologia e Hemoterapia 2014;36:226-229.
Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am 2006;26:515-534.
Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, et al. Hematology: basic principles and practice. 4th ed. Philadelphia: Elsevier, 2005;911-925.
Valent P, Escribano L, Broesby-Olsen S, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014;69:1267-1274.
Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996;108:385-397.
Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mas cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001;25:529-536.
Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635-641.
Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
Bonadonna P, Perbellini O, Passalacqa G, et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase level. J Allergy Clin Immunol 2009;123:680-686.
Frieri M, Quershi M. Pediatric mastocytosis: A review of the literature. Pediatr Allergy Immunol Pulmonol 2013;26:175-180.
Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013;13:693.
Akoglu G, Erkin G, Cakir B, Boztepe G, et al. Cutaneous mastocytosis: dermographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol 2006;20:969-973.
van Doormaal JJ, Arends S, Brunekreeft KL, et al. Prevalence of indolent systemic mastocytosis in a Dutcj region. JACI 2013;131:1429-1431.
Miettnen M, Lasota J. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunihistochem Mol Morphol 2005;13:205-220.
Quintas-Cardama A, Jain N, Verstovsek S. Advances and controversies in the diagnosis, pathogenesis and treatment of systemic mastocytosis. Cancer 2011;117:5439-5449.
Kambe N, Longley BJ, Miyachi Y, et al. KIT masters mast cells in kids, too. J Invest Dermatol 2010;130:648-650.
Bodemer C, Hermine O, Palmerini F, Yang Y, et al. Pediatric mastocytosis is a clinical disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-815.
Valent P, Spanbiochi E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood momonuclear cells by recombinant human stem cell factor/kit ligand in long term culture. Blood 1992;80:2237-2245.
Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell lines causing ligand-independent activation of c-kit product. J clin Invest 1993;92:1736-1744.
Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
Longley BJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609-1614.
Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: A clinical, KitD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900-904.
Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT- D816V systemic mastocytosis. Haematologica 2011;96:459-463.
Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome:
proposed diagnostic criteria. JACI 2010;126:1099-1104.
Belhacin W, Ibrahim Z, Grandne V, et al. Total serum tryptase levels are higher in young infants. Pediatr Allergy Immunol 2011;22:600-607.
Horny HP, Metcalfe DD, Benett JM, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC, 2008;54-63.
Valent P, Akin C, Esribano L, et al. Standards and standardization in mastocytosis consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112;946-956.
Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-5736.
Pardanani A. CME information: Systemic mastocytosis in adults: 2013, update on diagnosis, risk stratification, and management. Am J Hematol 2013;88:612.
Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010;115:150-151.
Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963;87:146-157.
Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: a long-term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer 2009;53:629-634.
Azaña JM, Torrelo A, Mediero IG, et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol 1994;11:102-106.
Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-5736.
Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunol Allergy Clin North Am 2014;34:181-196.
Horny HP, Stlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J Clin Pathol 2004;57:604-608.
Pardanani A, Reeder T, Li CY, et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003;27:883-885.
Brockow K. Urticaria pigmentosa. Immunol Allergy Clin North Am 2004;24:287-316.
Pardanani A. Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:401-411.
Kettelhut BV, Metcalfe DD. Mastocytosis. J Invest Dermatol 1991;96:115-118.
Brockow K, Jofer C, Behrendt H, et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-232.
Broesby-Olsen S, Kristensen T, Vestergaard H, et al. Kit D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. JACI 2013;132:723-728.
Florian S, Krauth MT, Simonitsch-Kulpp I, et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005;136:273-280.
Gulen T, Hagglund H, Dahlen B, et al. High prevalence of anaphylaxis in patients with systemic mastocytosis-a single center experience. Clin Exp Allergy 2013;44:121-129.
Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 2009;64:1379-1382.
Potier A, Lavigne C, Chappard D, et al. Cutaneous manifestations in hymenoptera and diptera anaphylaxis: relationship with basal serum tryptase. Clin and Exp Allergy 2009;39:717-725.
Gonzalez de Olano D, De la Hoz Caballero B, Nuñez Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exper Allergy 2007;37:1547-1555.
Dugas-Breit S, Przybilla B, Dugas M, et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010;40:643-649.
Guillaume N, Desoutter J, Chandesris O, et al. Bone complications of mastocytosis: a link between clinical and biological characterstics. Am J Med 2013;126:1-7.
Mathew R, Dhillon V, Sheperd P. Systemic mastocytosis presenting as osteoporosis-a case report. Clinical Rheumatology 2009;28:865-866.
Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment, recommendations and response criteria. Eur J Clin Invest 2207;37:435-453.
Heide R, van Doorn K, Mulder PG. Serum tryptase and SCORMA Index as disease severity parameters in childhood and adult cutaneous mastocytosis. Clin Exp Dermatol 2009;34:462-468.
Lange M, Boguslaw N, Gorska A, et al. Mastocytosis in children and adults; clinical disease heterogeneity. Arch Med Sci 2012;8:533-541.
Parker RI. Hematologic aspects of mastocytosis. I: Bone marrow pathology in adult and pediatric systemic mast cell disease. J Invest Dermatol 1991;96:47-51.
Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-1140.
Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002;127:115-117.
Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: A novel immunohistochemical marker for the diagnosis of SM in routenily processed bone marrow biopsy specimens. Am J
Surg Pathol 2004,28:1319-1325.
Sperr WR, El Samahi A, Kundi M, et al. Elevated tryptasa levels selectively cluster in myeloid neoplasm: A novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009;39:914-923.
Akin C. Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn 2006;8:412-419.
Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117 and bcl-x. Hum Pathol 2001;32:545-552.
Sotlar K, Cerny S, Petat K, et al. Aberrant expression of CD30 in neoplastic mast cells in high grade mastocytosis. Mod Pathol 2011;24:585-595.
Escribano L, García Montero AC, Núñez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: Role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am 2006;26:553-547.
Siebenhaar F, Fortsh A, Krause K, et al. Rupatadine improves quality of life in mastocytosis: a randomized, double blind, placebo-controlled trial. Allergy 2013;68:949-952.
Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000;14:579-623.
Sokol H, Georgin-Lavialle S, Canioni D, et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. JACI 2013;132:866-873.
Moura DS, Sultan S, Gerogin-Lavialle S, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PloS One 2012;7:39468.
Moura DS, Sultan S, Georgin-Lavialle S, et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PloS One 2011;6:26375.
Johnstone PA, Mican JM, Metcalfe DD, et al. Radiotherapy of refractory bone pain due to systemic mast cell disease. AM J Clin Oncol 1995;17:328-330.
Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. JACI 1990;85:852-855.
Lim AY, Ostor AJ, Love S, et al. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphpsphonate tratment. Ann Rheum Dis 2005;64:965-966.
Gonzalez de Olano, Alvarez Twose, Esteban Lopez M, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with hymenoptera venom anaphylaxis. JACI 2008;121:519-526.
Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998;138:489-495.
Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high dose interferon-alfa: Long term follow up of a case. Leuk Res 2005;29:131-134.
Kolde G, Sunderkotter C, Luger TA. Treatment of urticaria pigmentosa using interferon alpha. BR J Dermatol 1995;133:91-94.
Hauswirth AW, Simonitsch I, Uffmann M, et al. Response to therapy with interferon alpha 2b and prednisilone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004;28:249-257.
Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon aplha, hydroxiurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790-794.
Simon J, Lortholary O, Caillat Vigneron N, et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 2004;52:294-299.
Bohm A, Sonneck K, Gleixner KV, et al. In vitro and in vivo growth-inhibitory effects of claridibine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010;38:744-755.
Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expression the D816V mutated variant of KIT: Comparison with AMN107, imatinib and cladribine and evaluation. Blood
;107:752-759.
Escribano C, Akin M, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002;81:677-690.
Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. NEJM 2004;350:735-736.
Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the
treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. JACI 2007;119:1550-1551.
Sokol K, Ghazi A, Kelly B, et al. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract 2014;2:266-270.
Douglass JA, Carroll K, Voskamp A, et al. Omalizumab is effective in treating systemic mastocytosis in a non-atopic patient. Allergy 2010;65:926-927.
Matito A, Blazquez-Goni C, Morgado JM, et al. Short-term omalizumab treatment in an adolescent wuth cutaneous mastocytosis. Ann Allergy Asthma Immunol 2013;111:425-426.
Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. JACi 2007;119:1550-1551.
Siebenhaar F, Kühn W, Zuberbier T, et al. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol 2007;120:213-215.
Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
Alvarez-Twose I, Gonzalez P, Morgado JM, et al. Complete response after imatinib mesylate therapy in a patient with well-diferentiated systemic mastocytosis. J Clin Oncol 2012;30:126-129.
Gotlib J, Kluin-Nelemans HC, George Ti, et al. KIT inhibitor midostaurin in patients with advances systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012;120:799.
Bains SN, Hsieh FH. Current approaches to the diagnosis and treatment of systemic mastocytosis. Ann Allergy Asthma Immunol 2010;104:1-10.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2015 Revista Alergia México